目的 研究生血宝合剂联合利妥昔单抗注射液治疗自身免疫性溶血性贫血的临床疗效。方法 选取2017年12月-2018年12月绵阳市中心医院收治的80例自身免疫性溶血性贫血患者为研究对象，将所有患者随机分为对照组和治疗组，每组各40例。对照组患者静脉注射利妥昔单抗注射液，100 mg次加入到5%葡萄糖溶液中，稀释到1 mg/mL，1次/周；治疗组在对照组基础上口服生血宝合剂，15 mL/次，3次/d。两组患者持续治疗30 d。观察两组的临床疗效，比较两组的生化指标水平、免疫功能指标。结果 治疗后，对照组和治疗组的总有效率分别为77.50%、92.50%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者红细胞计数（RBC）和血红蛋白（HGB）水平均显著升高，网织红细胞百分率（Ret）水平显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患者生化指标水平明显优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患者CD3⁺、CD4⁺、CD4⁺/CD8⁺、NK水平均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组免疫功能指标水平显著高于对照组，两组比较差异有统计学意义（P<0.05）。结论 生血宝合剂联合利妥昔单抗注射液治疗自身免疫性溶血性贫血具有较好的治疗效果，可改善免疫功能，调节RBC、HGB、Ret水平，具有一定的临床推广应用价值。

Objective To study the efficacy of Shengxuebao Mixture combined with Rituximab Injection in treatment of autoimmune hemolytic anemia. Methods Patients (80 cases) with autoimmune hemolytic anemia in Mianyang Central Hospital from December 2017 to December 2018 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were iv administered with Rituximab Injection, 100 mg added into 5% glucose solution, and diluted to 1 mg/mL, once weekly. Patients in the treatment group were po administered with Shengxuebao Mixture on the basis of the control group, 15 mL/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacies were evaluated, and biochemical index levels and immune function indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.50% and 92.50%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of RBC and HGB in two groups were significantly increased, but the levels of Ret in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the biochemical index levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, CD4⁺/CD8⁺, and NK in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the immune function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shengxuebao Mixture combined with Rituximab Injection has clinical curative effect in treatment of autoimmune hemolytic anemia, can improve immune function, regulate the levels of RBC, HGB and Ret, which has a certain clinical application value.